Revenue Update on Aradigm Corporation(NASDAQ:ARDM)

Aradigm Corporation(NASDAQ:ARDM) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 28, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $125.000K. Analysts estimated a revenue of $10.000K. The revenues were 1,150% below the estimates. Earnings per share were $-0.54. The reported EPS was below estimates by -45.95%. Analysts had estimated an EPS of $-0.37.

Aradigm Corporation (ARDM) made into the market gainers list on Fridays trading session with the shares advancing 11.04% or 0.17 points. Due to strong positive momentum, the stock ended at $1.71, which is also near the day’s high of $1.71. The stock began the session at $1.59 and the volume stood at 24,521 shares. The 52-week high of the shares is $7.1882 and the 52 week low is $1.4. The company has a current market capitalization of $26 M and it has 1,49,51,089 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Oct 5, 2016, Juergen Kurt Froehlich (Chief Medical Officer) sold 423 shares at $6.76 per share price.

Aradigm Corporation is a pharmaceutical company. The Company is focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin which is in Phase III clinical trials. The Company also invested on AERx pulmonary drug delivery platform and other technologies. The Company’s partnered programs under development include Inhaled Ciprofloxacin. The Company is also developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine) program. Its lead development candidates are the Company’s formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with severe respiratory diseases such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF).

Add Comment